Edition:
United States

Ra Pharmaceuticals Inc (RARX.OQ)

RARX.OQ on NASDAQ Stock Exchange Global Market

9.13USD
1:57pm EDT
Change (% chg)

$-0.03 (-0.33%)
Prev Close
$9.16
Open
$9.10
Day's High
$9.32
Day's Low
$8.68
Volume
51,992
Avg. Vol
89,114
52-wk High
$23.55
52-wk Low
$4.93

Chart for

About

Ra Pharmaceuticals, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement... (more)

Overall

Beta: --
Market Cap(Mil.): $327.97
Shares Outstanding(Mil.): 32.31
Dividend: --
Yield (%): --

Financials

  RARX.OQ Industry Sector
P/E (TTM): -- 244.60 33.54
EPS (TTM): -2.51 -- --
ROI: -54.00 -5.33 13.09
ROE: -55.27 -6.88 15.10

BRIEF-Ra Pharma - Entered Sales Agreement With Stifel Pursuant To Which Co May Sell, Up To $50 Mln Of Shares Of Common Stock

* RA PHARMA - ENTERED SALES AGREEMENT WITH STIFEL PURSUANT TO WHICH CO MAY SELL, UP TO $50 MILLION OF SHARES OF COMMON STOCK, THROUGH STIFEL AS SALES AGENT Source text: (https://bit.ly/2G0vejI) Further company coverage:

May 09 2018

BRIEF-Ra Pharmaceuticals Q1 Loss Per Share $0.61

* RA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 09 2018

BRIEF-Ra Pharmaceuticals Announces Presentation Of RA101495 SC Phase 2 gMG Clinical Trial Design At 70Th Annual AAN Meeting

* RA PHARMACEUTICALS ANNOUNCES PRESENTATION OF RA101495 SC PHASE 2 GMG CLINICAL TRIAL DESIGN AT THE 70TH ANNUAL AAN MEETING

Apr 25 2018

BRIEF-Ra Pharmaceuticals Reports Q4 Loss Per Share $0.67

* RA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Mar 14 2018

BRIEF-Ra Pharmaceuticals Says Public Offering Of 8.40 Mln Common Shares Priced At $6.00/Share

* RA PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

Feb 14 2018

BRIEF-Ra Pharmaceuticals Announces Proposed Public Offering Of Common Stock

* RA PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Feb 13 2018

BRIEF-Ra Pharmaceuticals Initiates Dosing In Phase 1B Pharmacokinetic Study Evaluating Ra101495 Sc In Patients With Renal Impairment

* RA PHARMACEUTICALS INITIATES DOSING IN PHASE 1B PHARMACOKINETIC STUDY EVALUATING RA101495 SC IN PATIENTS WITH RENAL IMPAIRMENT Source text for Eikon: Further company coverage:

Jan 08 2018

Earnings vs. Estimates